EurekAlert! Cancer Research - News Releases

News Releases

Updates every hour. Last Updated: 11-Jul-2025 13:10 ET (11-Jul-2025 17:10 GMT/UTC)

Blood test could guide use of anti-inflammatory drug celecoxib to reduce risk of colon cancer recurrence

Dana-Farber Cancer Institute
Reports and Proceedings

A data analysis from a randomized clinical trial for stage 3 colon cancer patients by investigators at Dana-Farber Brigham Cancer Center found that patients with evidence of residual cancer in their blood after surgery to remove the cancer, may benefit from adding of celecoxib, to post surgery treatment.

Meeting: ASCO GI

Blood test from Alliance trial guides use of anti-inflammatory drug to lower colon cancer recurrence risk

Alliance for Clinical Trials in Oncology
Reports and Proceedings

The Alliance for Clinical Trials in Oncology today announced the results of a data analysis from a randomized phase III clinical trial involving patients with stage III colon cancer, which found that adding the drug celecoxib to treatment after surgery might help those who still have traces of cancer in their blood. The analysis showed that patients with signs of cancer in their blood measured by Signatera™, a circulating tumor DNA (ctDNA) test, tended to have worse outcomes. However, those who took celecoxib after surgery had a much better chance of staying cancer-free. These results are being presented in a late-breaking abstract and highlighted in the press program during the 2025 American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) Symposium, in San Francisco, CA.

New dyes pave way for better photothermal cancer treatment and diagnosis

Tokyo Metropolitan University
Peer-Reviewed Publication

Tokyo, Japan – Researchers from Tokyo Metropolitan University have developed a new dye that can strongly absorb second near-IR radiation and transform it to heat. Starting with a dye from the bile pigment family, they designed a unique ring structure which can bind rhodium and iridium. Measurements and modeling revealed strong second near-IR absorptions and exceptional photostability. Second near-IR waves easily penetrate human tissue; the new dye may be applied in deep tissue therapies and imaging.

Journal: Angewandte Chemie

Scientists design peptides to enhance drug efficacy

Advanced Science Research Center, GC/CUNY
Peer-Reviewed Publication

A team of scientists has developed a groundbreaking approach using specially designed peptides to improve drug formulations. This innovative method significantly enhances anti-tumor efficacy.

Journal: Chem

EMBARGOED: Dana-Farber investigators pinpoint keys to cell therapy response for leukemia

Dana-Farber Cancer Institute
Peer-Reviewed Publication

Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a standard therapy for patients with acute myeloid leukemia (AML) who have relapsed after allogenic hematopoietic stem cell transplant, will successfully move the patient into remission. The team identified that a key cell type in the DLI product and features of the tumor microenvironment in patients both play a role.

Journal: Science Immunology

Study unveils key immune cells found to boost cancer treatment success in acute myeloid leukemia

Columbia University School of Engineering and Applied Science
Peer-Reviewed Publication

A research team from Columbia Engineering and the Irving Institute for Cancer Dynamics made a pivotal discovery in the field of cancer immunotherapy. In a paper published today in Science Immunology, the team identified a specific population of immune cells that play a critical role in successful treatment of relapsed acute myeloid leukemia (AML).

Funder: Leukemia and Lymphoma Society, NIH/National Cancer Institute, NIH/National Human Genome Research Institute

Surgeon preference factors into survival outcomes analyses for multi- and single-arterial bypass grafting

The Society of Thoracic Surgeons
Meeting Announcement

A study presented this week at The Society of Thoracic Surgeons’ 61st Annual Meeting explores findings in more than a million U.S. Medicare beneficiaries who underwent CABG from 2001 to 2019. The researchers found that patients who received multi-arterial grafting (MAG) had improved survival over those who received single-arterial grafting (SAG), supporting findings from prior retrospective studies.

University Hospitals Seidman Cancer Center is one of the first in North America to offer Varian Ethos 2.0 for cancer patients

University Hospitals Cleveland Medical Center
Business Announcement

Radiation oncologists at UH Seidman Cancer Center have another powerful treatment option for patients diagnosed with many forms of cancer with the addition of Varian Ethos 2.0, capable of a new form of radiotherapy called adaptive radiotherapy.

Targeting potassium channel shows promise for treating brain tumours

The Hospital for Sick Children
Peer-Reviewed Publication

Researchers find blocking the KCNB2 gene can slow tumour growth, paving the way for next-gen treatments for childhood brain cancer.

Journal: Developmental Cell

Radiotherapy with Cetuximab may be superior to radiotherapy alone for selected patients who underwent surgery for head and neck cancer

NRG Oncology
Reports and Proceedings

Recent results from the phase III NRG Oncology RTOG 0920 (NRG-RTOG 0920) trial assessing postoperative radiotherapy with or without concurrent cetuximab for selected patients with squamous cell cancer of the head and neck (SCCHN) showed that radiotherapy with cetuximab demonstrated superiority as measured by improved disease-free survival, a secondary endpoint. The study also showed no increase in long-term toxicity. The trial results, however, did not show a statistically significant improvement in overall survival, the primary endpoint.

Journal: Journal of Clinical Oncology